Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib in Recurrent Ovarian, Primary Peritoneal and Fallopian Tube Cancer
NCT02278783Phase 2Terminated
- Sponsor
- University of Utah
- Start
- Mar 2015
- Primary completion
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of regorafenib in ovarian cancer, primary peritoneal cancer (PPC), fallopian tube cancer (PFTC), sponsored by University of Utah. Started Mar 2015; status: terminated.
02
Drugs
regorafenib
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT02278783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02278783.